LOGIN  |  REGISTER
Astria Therapeutics
Compass Therapeutics

CooperCompanies Declares Cash Dividend

December 14, 2022 | Last Trade: US$90.64 0.89 0.99

SAN RAMON, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO) today announced that consistent with the plan approved by its board of directors to pay annual dividends, the Company declared a semi-annual dividend of 3 cents per share, payable on February 10, 2023, to stockholders of record on January 23, 2023.

About CooperCompanies

CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of roughly 14,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.

Contact:

Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB